Skip to content
Search

Latest Stories

Tax authorities seek ‘liquidation of Liberty units’

BRITAIN'S tax authorities have requested the liquidation of several subsidiaries of British Indian billionaire Sanjeev Gupta's Liberty Steel due to £26 million in unpaid debts, media reported Thursday (10).

The Financial Times, citing documents filed in court this week, said authorities are seeking the liquidation of the Speciality Steel UK, Liberty Pipes, Liberty Performance Steels and Liberty Merchant Bar subsidiaries.

Sky News also reported the move to liquidate the units, adding the case should be taken up by the court this month.

The request by HM Revenue and Customs could topple Liberty Steel and put 3,000 UK jobs at risk.

Gupta was once seen as the saviour of British steelmaking, but one of the world's top steel groups has been fighting for survival following the collapse last March of Greensill Capital, the main lender to its parent company Gupta Family Group (GFG) Alliance.

A Liberty Steel spokesman said the company is "committed to repaying all our creditors" and was working to find an amicable solution.

"Short-term actions that risk destabilising these efforts are not in anyone’s interest," added the spokesman.

HMRC declined to comment on particular cases, but said it takes a "supportive approach to dealing with customers who have tax debts, working with them to find the best possible solution based on their financial circumstances".

Since the collapse of Greensill, which specialised in short-term corporate loans via a complex and opaque business model, GFG Alliance has been scrambling to restructure and cut costs to survive.

It announced the sale of two car parts factories in Britain and the closure of a third.

But it also injected 50 million pounds into one Liberty Steel site to restart production, saving 660 jobs, while the steelmaker is seeking to sell several other UK facilities.

GFG Alliance, which employs 35,000 throughout the world, is also under investigation for fraud and money laundering in its business activities, including in connection with the collapse of Greensill.

(AFP)

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less